SAB Biotherapeutics (SABS) CEO awarded 4,800,000 long-term stock options

Rhea-AI Filing Summary

SAB Biotherapeutics reported that CEO and director Samuel J. Reich received a grant of stock options on 02/03/2026. The award covers 4,800,000 options to buy common stock at an exercise price of $4.45 per share under the company’s 2021 Omnibus Equity Incentive Plan.

The options vest over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in 36 equal monthly installments. All 4,800,000 options are held directly by Reich and are scheduled to expire on 02/03/2036, aligning his potential compensation with longer-term company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Samuel J

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.45	02/03/2026		A		4,800,000(1)		(2)	02/03/2036	Common Stock	4,800,000	$0	4,800,000	D

Explanation of Responses:

1. Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

2. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

	/s/ Samuel J. Reich	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SAB Biotherapeutics (SABS) disclose about its CEO in this Form 4?

The filing shows CEO Samuel J. Reich received 4,800,000 stock options on 02/03/2026. These options allow him to purchase SAB Biotherapeutics common stock at $4.45 per share, aligning his compensation with future share price performance over a long-dated option term.

How many SAB Biotherapeutics (SABS) options were granted to the CEO and at what price?

Samuel J. Reich was granted 4,800,000 stock options with an exercise price of $4.45 per share. The options were issued under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan and give him the right to buy common shares at that fixed price.

What is the vesting schedule for the SAB Biotherapeutics (SABS) CEO’s new options?

The options vest over four years. One-quarter of the 4,800,000 options vests on the one-year anniversary of the grant date, with the remaining three-quarters vesting monthly in 36 equal installments, providing gradual ownership incentives over time.

When do the SAB Biotherapeutics (SABS) CEO’s stock options expire?

The CEO’s 4,800,000 stock options are scheduled to expire on 02/03/2036. This long expiration period gives Samuel J. Reich a multi-year window to exercise the options if SAB Biotherapeutics’ share price moves above the $4.45 exercise price.

Under which plan were the SAB Biotherapeutics (SABS) CEO’s options granted?

The options were granted under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended. This plan governs equity-based compensation, allowing the company to issue stock options that link executive pay to long-term shareholder value and company performance.

Does Samuel J. Reich hold the SAB Biotherapeutics (SABS) options directly or indirectly?

The Form 4 indicates that all 4,800,000 stock options are held directly by Samuel J. Reich. There is no footnote indicating indirect ownership through an entity, so the options are attributed personally to the CEO.